Ikena Oncology (NASDAQ:IKNA) Earns “Buy” Rating from HC Wainwright

Ikena Oncology (NASDAQ:IKNA)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They currently have a $4.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 127.27% from the stock’s previous close.

Separately, Wedbush restated a “neutral” rating and set a $2.00 target price on shares of Ikena Oncology in a report on Thursday, November 7th.

Ikena Oncology Trading Up 0.6 %

Shares of NASDAQ IKNA opened at $1.76 on Monday. Ikena Oncology has a 12 month low of $1.22 and a 12 month high of $2.32. The firm has a market capitalization of $84.93 million, a price-to-earnings ratio of -1.43 and a beta of 0.48. The business has a 50-day moving average of $1.70 and a 200-day moving average of $1.64.

Ikena Oncology (NASDAQ:IKNA) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.08. On average, analysts predict that Ikena Oncology will post -1.03 earnings per share for the current year.

Hedge Funds Weigh In On Ikena Oncology

Several hedge funds have recently made changes to their positions in IKNA. Acadian Asset Management LLC boosted its holdings in Ikena Oncology by 1,201.8% in the first quarter. Acadian Asset Management LLC now owns 282,782 shares of the company’s stock valued at $400,000 after acquiring an additional 261,060 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its stake in Ikena Oncology by 813.7% in the first quarter. Jacobs Levy Equity Management Inc. now owns 513,440 shares of the company’s stock worth $729,000 after buying an additional 457,245 shares in the last quarter. Deuterium Capital Management LLC purchased a new stake in Ikena Oncology in the second quarter worth about $133,000. BBR Partners LLC bought a new stake in Ikena Oncology during the 2nd quarter valued at approximately $33,000. Finally, JBF Capital Inc. purchased a new position in shares of Ikena Oncology during the 2nd quarter worth approximately $120,000. 75.00% of the stock is owned by hedge funds and other institutional investors.

About Ikena Oncology

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.